Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Surrozen, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Surrozen Provides Second Quarter 2023 Financial Results SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023 Corporate prioritization efforts expected to provide cash runway extension into 2025 SOUTH SAN FRANCISCO, Calif., August 9, 2023 -- Surrozen, Inc. , a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided second quarter 2023 financial results and corporate and pipeline updates. “During the second quarter of 2023, we made important progress in the Phase 1a clinical trials f..."
05/10/2023 8-K Quarterly results
Docs: "SURROZEN, INC. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 8,086 $ 9,371 General and administrative 5,299 5,122 Restructuring 1,207 — Total operating expenses 14,592 14,493 Loss from operations Interest income 547 49 Other income , net 6,497 Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 29,971 34,863 SURROZEN, INC. Condensed Consolidated Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 27,809 $ 24,690 Accounts receivable 1,978 1,978 Short-term marketable securities 33,937 51,148 Prepaid expen..."
03/22/2023 8-K Quarterly results
Docs: "SURROZEN, INC. Consolidated Statements of Operations and Comprehensive Loss Year Ended December 31, 2022 2021 Collaboration and license revenue $ 12,500 $ — Operating expenses: Research and development 37,013 40,177 General and administrative 19,826 14,214 Total operating expenses 56,839 54,391 Loss from operations Interest income 781 72 Other income , net 7,554 Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 34,722 24,689 SURROZEN, INC. Consolidated Balance Sheets December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 24,690 $ 33,091 Accounts receivable 1,978 — Short-term marketable securities 51,148 68,760 Prepa..."
08/11/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "Surrozen, Inc. Consolidated Statements of Operations Year Ended December 31, 2021 2020 Operating expenses: Research and development $ 40,177 $ 25,684 General and administrative 14,214 7,123 Total operating expenses 54,391 32,807 Loss from operations Interest income 72 91 Other expense, net — Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 24,689,339 15,972,348 Surrozen, Inc. Consolidated Balance Sheet Data December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 33,091 $ 34,982 Short-term marketable securities 68,760 14,200 Prepaid expenses and other current assets 3,338 1,042 Total current assets 105,189 50,224 Pro..."
11/15/2021 8-K Quarterly results
Docs: "Surrozen, Inc. Condensed Consolidated Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Operating expenses: Research and development $ 10,418 $ 6,958 $ 29,284 $ 17,034 General and administrative 3,287 1,683 10,112 4,937 Total operating expenses 13,705 8,641 39,396 21,971 Loss from operations Interest income 14 6 30 82 Other expense, net — — Net loss Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 27,401,956 18,507,423 21,291,480 15,261,552 Surrozen, Inc. Condensed Consolidated Balance Sheet Data Assets Current assets: Cash and cash equivalents $ 61,096 $ 34,982 Prepaid expenses..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy